Ecopipam (hydrobromide)

CAT:
804-HY-110033
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Ecopipam (hydrobromide) - image 1

Ecopipam (hydrobromide)

  • Description:

    Ecopipam (SCH 39166) hydrobromide is a potent, selective and orally active antagonist of dopamine D1/D5 receptor, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam hydrobromide shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively) . Ecopipam hydrobromide can be used for the research of schizophrenia and obesity[1].
  • Product Name Alternative:

    SCH 39166 (hydrobromide)
  • UNSPSC:

    12352005
  • Target:

    5-HT Receptor; Adrenergic Receptor; Dopamine Receptor
  • Type:

    Reference compound
  • Related Pathways:

    GPCR/G Protein; Neuronal Signaling
  • Applications:

    Metabolism-protein/nucleotide metabolism
  • Field of Research:

    Metabolic Disease; Neurological Disease
  • Assay Protocol:

    https://www.medchemexpress.com/sch-39166-hydrobromide.html
  • Purity:

    99.0
  • Solubility:

    10 mM in DMSO
  • Smiles:

    CN1[C@]2([H])[C@@](C3=CC=CC=C3CC2)([H])C4=CC(O)=C(Cl)C=C4CC1.Br
  • Molecular Formula:

    C19H21BrClNO
  • Molecular Weight:

    394.73
  • References & Citations:

    [1]Wu WL, et al. Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. J Med Chem. 2005 Feb 10;48 (3) :680-93.|[2]Sharopov S, et al. Dopaminergic modulation of low-Mg²⁺-induced epileptiform activity in the intact hippocampus of the newborn mouse in vitro. J Neurosci Res. 2012 Oct;90 (10) :2020-33.|[3]Satanove DJ, et al. Nicotine-induced enhancement of a sensory reinforcer in adult rats: antagonist pretreatment effects. Psychopharmacology (Berl) . 2021 Feb;238 (2) :475-486.|[4]R E Chipkin, et al. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther. 1988 Dec;247 (3) :1093-102. |[5]E Acquas, et al. Local application of SCH 39166 reversibly and dose-dependently decreases acetylcholine release in the rat striatum. Eur J Pharmacol. 1999 Nov 3;383 (3) :275-9.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -20°C (Powder, sealed storage, away from moisture)
  • Scientific Category:

    Reference compound1
  • Clinical Information:

    Phase 3
  • Isoform:

    D1 Receptor; D2 Receptor; D4 Receptor; D5 Receptor; MUC4; α adrenergic receptor
  • CAS Number:

    [2587360-22-1]